Axiom Investors LLC DE Lowers Position in Merit Medical Systems, Inc. $MMSI

Axiom Investors LLC DE cut its holdings in shares of Merit Medical Systems, Inc. (NASDAQ:MMSI) by 19.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 124,750 shares of the medical instruments supplier’s stock after selling 30,990 shares during the quarter. Axiom Investors LLC DE’s holdings in Merit Medical Systems were worth $10,995,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of MMSI. Los Angeles Capital Management LLC purchased a new position in shares of Merit Medical Systems during the 4th quarter worth $25,000. Maseco LLP purchased a new position in Merit Medical Systems during the 4th quarter valued at about $26,000. Torren Management LLC purchased a new position in Merit Medical Systems during the 4th quarter valued at about $38,000. Covestor Ltd boosted its holdings in Merit Medical Systems by 252.6% during the 4th quarter. Covestor Ltd now owns 469 shares of the medical instruments supplier’s stock valued at $41,000 after acquiring an additional 336 shares during the period. Finally, Danske Bank A S purchased a new position in Merit Medical Systems during the 3rd quarter valued at about $42,000. 99.66% of the stock is currently owned by hedge funds and other institutional investors.

Merit Medical Systems Stock Performance

Shares of MMSI opened at $67.51 on Wednesday. The stock has a 50-day simple moving average of $65.67 and a 200-day simple moving average of $75.75. The company has a debt-to-equity ratio of 0.45, a quick ratio of 3.46 and a current ratio of 5.08. The stock has a market capitalization of $4.03 billion, a PE ratio of 29.23, a PEG ratio of 2.05 and a beta of 0.54. Merit Medical Systems, Inc. has a 1 year low of $59.74 and a 1 year high of $96.74.

Merit Medical Systems (NASDAQ:MMSI) last announced its quarterly earnings data on Thursday, April 30th. The medical instruments supplier reported $0.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.84 by $0.10. The business had revenue of $381.88 million during the quarter, compared to analysts’ expectations of $377.59 million. Merit Medical Systems had a return on equity of 13.54% and a net margin of 9.03%.The business’s quarterly revenue was up 7.4% compared to the same quarter last year. During the same quarter last year, the business posted $0.86 EPS. Merit Medical Systems has set its FY 2026 guidance at 4.010-4.150 EPS. On average, analysts predict that Merit Medical Systems, Inc. will post 3.62 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Lynne N. Ward sold 5,000 shares of Merit Medical Systems stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $62.61, for a total value of $313,050.00. Following the completion of the transaction, the director owned 7,809 shares in the company, valued at approximately $488,921.49. This trade represents a 39.04% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Brian G. Lloyd acquired 2,000 shares of the firm’s stock in a transaction dated Thursday, May 7th. The stock was bought at an average price of $62.62 per share, with a total value of $125,240.00. Following the purchase, the insider directly owned 2,000 shares in the company, valued at approximately $125,240. This trade represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Company insiders own 0.70% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Canaccord Genuity Group lowered their target price on Merit Medical Systems from $90.00 to $85.00 and set a “buy” rating for the company in a report on Friday, May 1st. Barrington Research lowered their target price on Merit Medical Systems from $109.00 to $107.00 and set an “outperform” rating for the company in a report on Monday, April 20th. Wall Street Zen cut Merit Medical Systems from a “strong-buy” rating to a “buy” rating in a report on Sunday, April 5th. Robert W. Baird set a $83.00 target price on Merit Medical Systems in a report on Friday, May 1st. Finally, Compass Point set a $107.00 target price on Merit Medical Systems in a report on Monday, April 20th. Eight investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Merit Medical Systems presently has an average rating of “Moderate Buy” and an average target price of $92.80.

About Merit Medical Systems

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.